NEW YORK, March 11, 2019 /PRNewswire/ -- Bridge Medicines announced today an agreement with Weill Cornell Medicine to develop a novel sphingosine 1-phosphate (S1P) receptor modulator. This small ...
Approval of the selective sphingosine-1-phosphate (S1P) receptor modulator was supported by the phase III ELEVATE UC program, which together included nearly 800 patients who had failed or were ...
Dublin, Ireland – 27 th November 2023 – Priothera Ltd., a Phase 3 clinical stage biotechnology company pioneering the development of its S1P receptor modulator compound mocravimod, today announced ...
Please provide your email address to receive an email when new articles are posted on . Cardiovascular risk-screening and stratification is advised for IBD patients before JAK inhibitor or S1P ...
Novartis’ multiple sclerosis therapy Gilenya was once proposed as a kidney disease treatment because its ability to modulate S1P receptors could theoretically tamp down inflammation. Although that ...
Presentations highlight efficacy of TRV045 in animal models of neuropathic pain and epilepsy TRV045 selectively targets the S1P 1 receptor without associated lymphopenia IND filing on track for 1H ...
CHESTERBROOK, Pa., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with ...
Etrasimod, a selective sphingosine 1-phosphate (S1P) receptor modulator that targets S1P receptor subtypes 1, 4, and 5 (S1P1,4,5), induces durable remission in UC, with 32% of patients achieving ...
The Food and Drug Administration (FDA) approved Pfizer Inc's (NYSE:PFE) Velsipity (etrasimod), an oral, once-daily, selective sphingosine-1-phosphate (S1P) receptor modulator for adults with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results